Skip to content

Calculus VCT – 3rd to close in the market

Wealth Club’s VCT Fundraising infographic shows the early closers in the VCT market, with the Calculus VCT in third place. Click the image below to open a larger version of the chart. Get in touch to register your interest for the next Calculus VCT fundraise: [email protected] 020 7493 4940 Offers are listed in the order … Continued

WheelRight retains top 20 position in IP100 Club

In a significantly larger field of entrants for 2017, WheelRight has retained its top 20 position in the IP100 league, coming in at 11th overall. The IP League is an annual ranking of businesses which are considered to be the most effective at commercialising their IP assets. The league, which was created by Metis Partners, ‘profiles … Continued

Jumptastic opens the biggest trampoline park in Denmark

Jumptastic has opened its first Scandinavian facility named Xjump, which is the largest trampoline park in Denmark and one of the largest in Europe. The site contains 250 trampolines spread out over different attractions and activities, spanning 5,500 square metres. In addition to UK growth plans, Jumptastic identified Scandinavia as a key expansion target. It is … Continued

Funding boost for pioneering biotech firm Synpromics

Calculus Capital’s investment in Synpromics was featured in national Scottish newspapers The Scotsman and The Herald. Synpromics is a Edinburgh-based synthetic biology company which Calculus Capital has backed for a second time, leading the new round with a £3.5m investment alongside backing from Scottish Enterprise and a group of private investors. The Scotsman spoke of the research … Continued

Calculus invests in Scottish biotech star Synpromics

Calculus Capital has invested a total of £3.5m in Scottish biotechnology company Synpromics, as part of a £5.2m fundraising round alongside the Scottish government’s economic development agency, Scottish Enterprise and a group of private investors. Edinburgh-based Synpromics is a developer of synthetic gene promoters. These are a vital component in the research and development of gene-based … Continued

Calculus Capital closes EIS fundraising three months early after hitting £20m target

London, April, 2017: Private equity fund manager Calculus Capital has closed its EIS fundraising after reaching its £20m target three months earlier than anticipated. John Glencross, Calculus Capital Chief Executive, said: “Appetite for investing in unlisted UK smaller companies through the Enterprise Investment Scheme has been growing year-on-year. And it’s not surprising, given the breadth, depth … Continued